Cryo-Cell International, Inc. (CCEL) operates one of the longest-running private umbilical cord blood and cord tissue banking businesses in the United States. Headquartered in Oldsmar, Florida, the company collects, processes, tests, and cryogenically stores newborn stem cells for families, and also runs a smaller public cord blood bank and sells its PrepaCyte CB processing technology.
In Monday's session, the stock was quoted at $4.34, down 10.52% from the prior completed session's close of $4.85. The direction is unambiguously negative. No verified news or fundamental catalyst was found for the decline; the move instead extends a sharp reversal that began in the previous session, when shares fell 10.19% from $5.40 after touching a 52-week high.
No verified news or fundamental catalyst found in the record explains Monday's decline. There was no earnings release — the company last reported fiscal third-quarter 2026 results on October 9, when it disclosed revenue of $7.82 million, essentially flat year over year, and net income of $1.27 million. There were no new SEC filings, no analyst rating changes, no financing announcements, and no regulatory or legal disclosures published between Friday's close and Monday's open. The most recent corporate news of note — shareholder approval of the board, auditor, and executive compensation at the October 27 annual meeting — was routine and long since absorbed by the market.
That leaves price mechanics. The most likely explanation is profit-taking after a steep run. The shares climbed from roughly $3.57 in early August to an intraday 52-week high near $5.45 on November 12, a gain of more than 50% in about three months, then reversed hard on November 13 and continued lower Monday. This pattern — an extended advance, a blow-off high, and a two-day giveback of nearly a fifth of the share price — is consistent with momentum traders exiting a crowded position rather than a change in business fundamentals.
The scale of the decline is best understood against the stock's trading profile. CCEL has a market capitalization of roughly $35 million on about 8.06 million shares outstanding, and average daily turnover of only around 13,000 shares. With an order book that thin, relatively modest sell interest can move the quote several percentage points.
The stock's own history supports that read. Over the last 60 sessions, the average absolute daily move has been about 4.2%, and the shares have posted moves of 10% or more on five occasions — including a 19.8% drop and a 17.8% rebound on consecutive days in late September, a 12.0% decline on October 15, a 21.1% rally the next session, and a 12.5% jump on October 26. Double-digit swings are a recurring feature of this micro-cap, not an anomaly. Monday's 10.52% decline was roughly 2.5 times the typical daily move.
Volume in the early session was modest and in line with the stock's normally light turnover, offering limited evidence of institutional repositioning. The move did not track any identifiable sector catalyst: cord blood and cellular therapy peers showed no comparable double-digit declines, and major U.S. indices were not displaying anything resembling a 10% risk-off session. With a beta of roughly 0.55 and very low correlation to large-cap benchmarks, the stock's swings are driven far more by its own flow dynamics than by macro conditions.
Technically, the pullback pushed the shares below their 50-day moving average of roughly $4.47, a level that had contained the rally since late September. The stock remains well above its longer-term trend and still holds a gain of roughly 20% from August levels, which is consistent with a correction inside an uptrend rather than a trend break. The $4.30–$4.35 zone, which coincides with the November 13 intraday low, is the first meaningful support level traders are now watching.
The score runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 16 out of 100.
Verified news strength was effectively zero: no filing, release, analyst action, or credible report preceded the decline, and nothing fundamental changed about a business whose latest quarter was already public in October. The price move was also only moderately unusual. At 10.52%, it was about 2.5 times the stock's typical daily move, and moves of equal or greater size have occurred five times in the last 60 sessions. A large move for most stocks is close to routine here, so the anomaly component stayed low. With both components weak, the combined score lands near the bottom of the scale.
The next scheduled fundamental test is the company's fiscal fourth-quarter and full-year 2026 results, expected in late February 2027 given its November 30 fiscal year-end. Investors will focus on processing and storage revenue trends, the durability of recent margin improvement, and cash generation against a stockholders' deficit that triggered a NYSE American listing-compliance notice earlier this year — a plan to regain compliance runs through September 2027.
Also relevant is the unresolved dispute with Duke University over a terminated license agreement, which has paused planned expansion into cellular therapy manufacturing and infusion clinics. Analyst coverage is sparse, with a single Hold rating and a wide dispersion of published expectations, so headline risk around any new contract, accreditation, or financing announcement is elevated. Until fundamentals reassert themselves, the shares are likely to stay sensitive to flow and momentum rather than to news.
Tickeron's Trending AI Robots page curates the automated strategies performing best under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers make this featured section. Bots differ widely by strategy logic, timeframe, performance metrics, and the symbols they trade, so the list shifts as conditions change. Reviewing it can help traders see which approaches are working right now and where they might fit into a broader plan.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CCEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 43 of 49 cases where CCEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 65 cases where CCEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
CCEL moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CCEL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +10.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCEL advanced for three days, in 150 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 79 of 97 cases where CCEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The 10-day RSI Indicator for CCEL moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 26 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCEL as a result. In 107 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CCEL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 45 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.220) is normal, around the industry mean (204.532). P/E Ratio (-15.774) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (2.680) is also within normal values, averaging (2.498). Dividend Yield (0.123) settles around the average of (0.154) among similar stocks. P/S Ratio (1.141) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement